Literature DB >> 29637440

Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.

Yogita Dheer1, Nitin Chitranshi2, Veer Gupta3, Mojdeh Abbasi2, Mehdi Mirzaei4, Yuyi You5, Roger Chung2, Stuart L Graham2,5, Vivek Gupta2.   

Abstract

Retinoid X-receptors (RXRs) are members of the ligand-dependent transcription factor family of nuclear receptors that have gained recent research focus as potential targets for neurodegenerative disorders. Bexarotene is an RXR pharmacological agonist that is shown to be neuroprotective through its effects in promoting amyloid beta (Aβ) uptake by the glial cells in the brain. This study aimed to evaluate the dose-dependent effects of bexarotene on RXR expression in SH-SY5Y neuroblastoma cells and validate the drug effects in the brain in vivo. The protein expression studies were carried out using a combination of various drug treatment paradigms followed by expression analysis using Western blotting and immunofluorescence. Our study demonstrated that bexarotene promoted the expression of RXR α, β and γ isoforms at optimal concentrations in the cells and in the mice brain. Interestingly, a decreased RXR expression was identified in Alzheimer's disease mouse model and in the cells that were treated with Aβ. Bexarotene treatment not only rescued the RXR expression loss caused by Aβ treatment (p < 0.05) but also protected the cells against Aβ-induced ER stress (p < 0.05) and pro-apoptotic BAD protein activation (p < 0.05). In contrast, higher concentrations of bexarotene upregulated the ER stress proteins and led to BAD activation. Our study revealed that these downstream neurotoxic effects of high drug concentrations could be prevented by pharmacological targeting of the TrkB receptor. The ER stress and BAD activation induced by high concentrations of bexarotene were rescued by the TrkB agonist, 7,8 dihydroxyflavone (p < 0.05) while TrkB inhibitor CTX-B treatment further exacerbated these effects. Together, these findings suggest a cross-talk of TrkB signalling with downstream effects of bexarotene toxicity and indicate that therapeutic targeting of RXRs could prevent the Aβ-induced molecular neurotoxic effects.

Entities:  

Keywords:  Amyloid beta; Bexarotene; ER stress; Retinoid-X-receptor; TrkB

Mesh:

Substances:

Year:  2018        PMID: 29637440     DOI: 10.1007/s12035-018-1041-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  11 in total

1.  Suppression of TLR4/MyD88/TAK1/NF-κB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.

Authors:  Sefika Pinar Senol; Meryem Temiz-Resitoglu; Demet Sinem Guden; Ayse Nihal Sari; Seyhan Sahan-Firat; Bahar Tunctan
Journal:  Neurochem Res       Date:  2021-01-02       Impact factor: 3.996

2.  Caveolin-1 Ablation Imparts Partial Protection Against Inner Retinal Injury in Experimental Glaucoma and Reduces Apoptotic Activation.

Authors:  Mojdeh Abbasi; Vivek K Gupta; Nitin Chitranshi; Veer B Gupta; Mehdi Mirzaei; Yogita Dheer; Linda Garthwaite; Thiri Zaw; Robert G Parton; Yuyi You; Stuart L Graham
Journal:  Mol Neurobiol       Date:  2020-06-23       Impact factor: 5.590

3.  Bexarotene Enhances Macrophage Erythrophagocytosis and Hematoma Clearance in Experimental Intracerebral Hemorrhage.

Authors:  Che-Feng Chang; Jordan Massey; Artem Osherov; Luís Henrique Angenendt da Costa; Lauren H Sansing
Journal:  Stroke       Date:  2019-12-12       Impact factor: 7.914

Review 4.  Retinoid X Receptor: Cellular and Biochemical Roles of Nuclear Receptor with a Focus on Neuropathological Involvement.

Authors:  Samridhi Sharma; Ting Shen; Nitin Chitranshi; Veer Gupta; Devaraj Basavarajappa; Soumalya Sarkar; Mehdi Mirzaei; Yuyi You; Wojciech Krezel; Stuart L Graham; Vivek Gupta
Journal:  Mol Neurobiol       Date:  2022-01-11       Impact factor: 5.682

Review 5.  Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects.

Authors:  Nitin Chitranshi; Yogita Dheer; Mojdeh Abbasi; Yuyi You; Stuart L Graham; Vivek Gupta
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

6.  Inner retinal injury in experimental glaucoma is prevented upon AAV mediated Shp2 silencing in a caveolin dependent manner.

Authors:  Mojdeh Abbasi; Vivek K Gupta; Nitin Chitranshi; Veer Gupta; Reza Ranjbaran; Rashi Rajput; Kanishka Pushpitha; Devaraj Kb; Yuyi You; Ghasem Hosseini Salekdeh; Robert G Parton; Mehdi Mirzaei; Stuart L Graham
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

7.  Exploiting protein family and protein network data to identify novel drug targets for bladder cancer.

Authors:  Tolulope Tosin Adeyelu; Aurelio A Moya-Garcia; Christine Orengo
Journal:  Oncotarget       Date:  2022-01-12

8.  Hypercholesterolemia and 27-Hydroxycholesterol Increase S100A8 and RAGE Expression in the Brain: a Link Between Cholesterol, Alarmins, and Neurodegeneration.

Authors:  Raúl Loera-Valencia; Muhammad-Al-Mustafa Ismail; Julen Goikolea; Maria Lodeiro; Laura Mateos; Ingemar Björkhem; Elena Puerta; Mariana A Romão; Cláudio M Gomes; Paula Merino-Serrais; Silvia Maioli; Angel Cedazo-Minguez
Journal:  Mol Neurobiol       Date:  2021-08-27       Impact factor: 5.590

9.  Determination of Alteration in Micromeritic Properties of a Solid Dispersion: Brunauer-Emmett-Teller Based Adsorption and Other Structured Approaches.

Authors:  Lovepreet Singh; Lakhvir Kaur; Gurjeet Singh; R K Dhawan; Manjeet Kaur; Navdeep Kaur; Prabhpreet Singh
Journal:  AAPS PharmSciTech       Date:  2022-07-28       Impact factor: 4.026

10.  Pharmacological Activation of RXR-α Promotes Hematoma Absorption via a PPAR-γ-dependent Pathway After Intracerebral Hemorrhage.

Authors:  Chaoran Xu; Huaijun Chen; Shengjun Zhou; Chenjun Sun; Xiaolong Xia; Yucong Peng; Jianfeng Zhuang; Xiongjie Fu; Hanhai Zeng; Hang Zhou; Yang Cao; Qian Yu; Yin Li; Libin Hu; Guoyang Zhou; Feng Yan; Gao Chen; Jianru Li
Journal:  Neurosci Bull       Date:  2021-06-17       Impact factor: 5.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.